leisure time -WSS

leisure time

author：explore 2025-09-30 14:53:31 - browse：7674

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Mitch McConnell episode has important public health takeaway

WSS

Male doctors called my cancer incurable. A female doctor showed it wasn't

Trump indictment: Who are the 'co

‘Oppenheimer’ and the risks of AI in health care

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

At JPM 2024, hospital systems pitch financial strength to investors

hotspot

leisure time

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

ChatGPT in medicine: STAT answers readers' burning questions

Arena BioWorks launches in Cambridge to speed drug discovery

Novavax promises a turnaround & Lilly roils the obesity market

No plane should take off without an EpiPen onboard

DIEP, the 'gold standard' of breast reconstruction, is under threat

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Trump demands the U.S. pay no more for drugs than other countries … again

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

hotspot

The high personal cost of affirmative action for Black doctors

No plane should take off without an EpiPen onboard

Micronoma's microbiome cancer diagnostic approach under fire

The high personal cost of affirmative action for Black doctors

The high personal cost of affirmative action for Black doctors

Vertex non

hotspot

explore

focus

leisure time